Tenax Therapeutics (TENX) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Downgraded | Buy → Neutral | — | Aug 31, 2026 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $5.00 from $39.00 | Aug 11, 2026 |
| Guggenheim | Maintained | Buy | $4.00 from $40.00 | Aug 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $4.00 from $35.00 | Aug 11, 2026 |
| Chardan Capital | Downgraded | Buy → Neutral | $5.00 from $27.00 | Aug 11, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 10, 2026 |
| Chardan Capital | Maintained | Buy | $27.00 | Jul 31, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $35.00 | Jul 29, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $35.00 | Jul 28, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $39.00 | Jul 22, 2026 |
| Chardan Capital | Maintained | Buy | $27.00 | Jul 2, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $35.00 | Jun 24, 2026 |
| Guggenheim | Maintained | Buy | $40.00 from $34.00 | Jun 22, 2026 |
| Chardan Capital | Initiated Coverage | Buy | $27.00 | Jun 22, 2026 |
| Piper Sandler | Maintained | Overweight | $50.00 from $20.00 | Jun 12, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $35.00 | Mar 17, 2026 |
| Guggenheim | Maintained | Buy | $34.00 from $25.00 | Mar 16, 2026 |
| Guggenheim | Maintained | Buy | $25.00 from $14.00 | Dec 17, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $20.00 | Sep 8, 2025 |
| Guggenheim | Maintained | Buy | $14.00 from $15.00 | Aug 14, 2025 |
Frequently asked questions
What is the price target for TENX stock?
The average 12-month analyst price target for Tenax Therapeutics (TENX) is $17.17, with a high estimate of $50.00 and a low of $4.00, across 6 analysts.
Is TENX a buy, sell, or hold?
Analysts covering Tenax Therapeutics currently average a Buy rating: 7 buy, 3 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for TENX?
The average price target of $17.17 implies 843.22% upside from the last price of $1.82.
What is the latest analyst rating on TENX?
On Aug 31, 2026, Guggenheim downgraded Tenax Therapeutics to Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.